{"result": {"id": "b1bafd82-5337-44c8-a2a8-7b61bcab8458", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>PATHWAY-2<|>EVENT<|>PATHWAY-2 is a randomized, double-blind, crossover trial comparing spironolactone with other treatments for drug-resistant hypertension\")\n##\n(\"entity\"<|>JET STUDY<|>EVENT<|>The JET study investigated the efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients\")\n##\n(\"entity\"<|>PRECISION<|>EVENT<|>PRECISION is a multicentre, blinded, randomized, parallel-group, phase 3 trial evaluating aprocitentan for resistant hypertension\")\n##\n(\"entity\"<|>START-STUDY<|>EVENT<|>The START-study examined improved persistence to medication and reduced cardiovascular events with single-pill combinations in hypertensive patients\")\n##\n(\"entity\"<|>SYMPLICITY HTN-2<|>EVENT<|>Symplicity HTN-2 is a multicentre safety and proof-of-principle cohort study on catheter-based renal sympathetic denervation for resistant hypertension\")\n##\n(\"relationship\"<|>WILLIAMS B<|>PATHWAY-2<|>Williams B is an author of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>MACDONALD TM<|>PATHWAY-2<|>MacDonald TM is an author of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>MORANT S<|>PATHWAY-2<|>Morant S is an author of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>YANO Y<|>JET STUDY<|>Yano Y is an author of the JET study<|>8)\n##\n(\"relationship\"<|>HOSHIDE S<|>JET STUDY<|>Hoshide S is an author of the JET study<|>8)\n##\n(\"relationship\"<|>TAMAKI N<|>JET STUDY<|>Tamaki N is an author of the JET study<|>8)\n##\n(\"relationship\"<|>SCHLAICH MP<|>PRECISION<|>Schlaich MP is an author of the PRECISION trial<|>8)\n##\n(\"relationship\"<|>BELLET M<|>PRECISION<|>Bellet M is an author of the PRECISION trial<|>8)\n##\n(\"relationship\"<|>WEBER MA<|>PRECISION<|>Weber MA is an author of the PRECISION trial<|>8)\n##\n(\"relationship\"<|>SCHMIEDER RE<|>START-STUDY<|>Schmieder RE is an author of the START-study<|>8)\n##\n(\"relationship\"<|>WASSMANN S<|>START-STUDY<|>Wassmann S is an author of the START-study<|>8)\n##\n(\"relationship\"<|>PREDEL HG<|>START-STUDY<|>Predel HG is an author of the START-study<|>8)\n##\n(\"relationship\"<|>KRUM H<|>SYMPLICITY HTN-2<|>Krum H is an investigator in the Symplicity HTN-2 study<|>8)\n##\n(\"relationship\"<|>SCHLAICH M<|>SYMPLICITY HTN-2<|>Schlaich M is an investigator in the Symplicity HTN-2 study<|>8)\n##\n(\"relationship\"<|>WHITBOURN R<|>SYMPLICITY HTN-2<|>Whitbourn R is an investigator in the Symplicity HTN-2 study<|>8)\n##\n(\"relationship\"<|>ESLER MD<|>SYMPLICITY HTN-2<|>Esler MD is an investigator in the Symplicity HTN-2 study<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559050, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 862, "prompt_tokens": 6716, "total_tokens": 7578, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3264}, "prompt_cache_hit_tokens": 3264, "prompt_cache_miss_tokens": 3452}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ) :26-38.\n[292]  Williams B, MacDonald TM, MorantS, et al.  Spironolactone versusplacebo, bisoprolol, and doxazosinto determinetheopti- maltreatmentfordrug-resistanthypertension(PATHWAY-2) :  a randomised, double-blind,  crossover trial[J]. Lancet, 2015,  386(10008) :2059-2068.\n[293]  Yano Y, Hoshide S, TamakiN, et al.  Efficacy of eplerenone\n\n\n　added to renin-angiotensin blockade in elderly hypertensive pa- tients: theJichi-EplerenoneTreatment(JET) study[J]. J Renin Angiotensin AldosteroneSyst,2011,12(3) :340-347.\n[294]  B?rfacker L,  KuhlA,  Hillisch A,  et al.  Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid re- ceptorfor the treatment of cardiorenaldiseases[J]. ChemMed- Chem,2012,7(8) :1385-1403.\n[295]  PatouliasD, PapadopoulosC, KaragiannisA, etal. Cardiovas- cularoutcomes with finerenone according to glycemic status at baselineand priortreatmentwith newerantidiabeticsamongpa- tientswith type2 diabetes mellitus[J]. EndocrinolMetab (Se- oul) ,2022,37(1) :170-174.\n[296]  SidhartaPN, MelchiorM, Kankam MK, etal. Single-andmul- tiple-dosetolerability, safety, pharmacokinetics, andpharmaco- dynamicsofthedualendothelin receptorantagonistaprocitentan in healthy adultand elderly subjects[J]. Drug Des DevelTher,  2019,13:949-964.\n[297]  Schlaich MP, BelletM, WeberMA, etal. Dualendothelin an- tagonistaprocitentan forresistanthypertension (PRECISION) :  a multicentre, blinded, randomised, parallel-group, phase3 tri- al[J]. Lancet,2022,400(10367) :1927-1937.\n[298]  TsapasA, KaragiannisT, KakotrichiP, etal.  Comparativeef- ficacyofglucose-lowering medicationson bodyweightand blood pressurein patients with type 2 diabetes: a systematic review and network meta-analysis[J]. Diabetes Obes Metab, 2021, 23\n(9) :2116-2124.\n[299]  SchmiederRE, WassmannS, PredelHG, etal.  Improved per- sistenceto medication, decreased cardiovascular events and re- duced all-cause mortality in hypertensive patients with use of single-pillcombinations: resultsfrom theSTART-study[J]. Hy- pertension,2023,80(5) :1127-1135.\n[300]  AlbasriA, HattleM, KoshiarisC, etal.  Association between antihypertensive treatment and adverse events:  systematic re- view and meta-analysis[J]. BMJ,2021,372:n189.\n[301]  SicaDA, CarterB, Cushman W , etal. Thiazide and loop diu- retics[J]. J Clin Hypertens(Greenwich) ,2011,13(9) :639-643.\n[302]  李立明 ,胡永华 ,曹卫华 ,等.  原发性高血压的社区综合防治研究 [J]. 北京大学学报(医学版) ,2002,34(5) :519-524.\n[303]  卫生部心血管病防治研究中心.  社区疾病管理教程[M]. 北京 : 中国大百科全书出版社 ,2009:123-128.\n[304]  梁小华 ,顾东风 ,张欢 ,等.  社区高血压患者健康管理药物治疗和  直接医疗费用分析[J]. 中华预防医学杂志 , 2011, 45(8) : 732- 736.\n[305]  刘克军 ,陈伟伟.  动态血压监测应用于社区高血压诊断的卫生经 济学评价[J]. 中国药物经济学 ,2020,15(11) :25-28.\n[306]  Krum H, SchlaichM, WhitbournR, etal. Catheter-basedrenal sympatheticdenervation for resistanthypertension: a multicen- tresafety and proof-of-principle cohort study[J]. Lancet, 2009,  373(9671) :1275-1281.\n[307]  Symplicity HTN-2 Investigators, Esler MD, Krum H,  et al.  Symp\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>WILLIAMS B<|>PERSON<|>Williams B is one of the authors of the PATHWAY-2 study on spironolactone for drug-resistant hypertension\")\n##\n(\"entity\"<|>MACDONALD TM<|>PERSON<|>MacDonald TM is one of the authors of the PATHWAY-2 study on spironolactone for drug-resistant hypertension\")\n##\n(\"entity\"<|>MORANT S<|>PERSON<|>Morant S is one of the authors of the PATHWAY-2 study on spironolactone for drug-resistant hypertension\")\n##\n(\"entity\"<|>YANO Y<|>PERSON<|>Yano Y is one of the authors of the JET study on eplerenone in elderly hypertensive patients\")\n##\n(\"entity\"<|>HOSHIDE S<|>PERSON<|>Hoshide S is one of the authors of the JET study on eplerenone in elderly hypertensive patients\")\n##\n(\"entity\"<|>TAMAKI N<|>PERSON<|>Tamaki N is one of the authors of the JET study on eplerenone in elderly hypertensive patients\")\n##\n(\"entity\"<|>B?RFACKER L<|>PERSON<|>B?rfacker L is one of the authors of the study on BAY 94-8862, a nonsteroidal antagonist of the mineralocorticoid receptor\")\n##\n(\"entity\"<|>KUHL A<|>PERSON<|>Kuhl A is one of the authors of the study on BAY 94-8862, a nonsteroidal antagonist of the mineralocorticoid receptor\")\n##\n(\"entity\"<|>HILLISCH A<|>PERSON<|>Hillisch A is one of the authors of the study on BAY 94-8862, a nonsteroidal antagonist of the mineralocorticoid receptor\")\n##\n(\"entity\"<|>PATOULIAS D<|>PERSON<|>Patoulias D is one of the authors of the study on cardiovascular outcomes with finerenone in patients with type 2 diabetes mellitus\")\n##\n(\"entity\"<|>PAPADOPOULOS C<|>PERSON<|>Papadopoulos C is one of the authors of the study on cardiovascular outcomes with finerenone in patients with type 2 diabetes mellitus\")\n##\n(\"entity\"<|>KARAGIANNIS A<|>PERSON<|>Karagiannis A is one of the authors of the study on cardiovascular outcomes with finerenone in patients with type 2 diabetes mellitus\")\n##\n(\"entity\"<|>SIDHARTA PN<|>PERSON<|>Sidharta PN is one of the authors of the study on the dual endothelin receptor antagonist aprocitentan\")\n##\n(\"entity\"<|>MELCHIOR M<|>PERSON<|>Melchior M is one of the authors of the study on the dual endothelin receptor antagonist aprocitentan\")\n##\n(\"entity\"<|>KANKAM MK<|>PERSON<|>Kankam MK is one of the authors of the study on the dual endothelin receptor antagonist aprocitentan\")\n##\n(\"entity\"<|>SCHLAICH MP<|>PERSON<|>Schlaich MP is one of the authors of the PRECISION study on aprocitentan for resistant hypertension\")\n##\n(\"entity\"<|>BELLET M<|>PERSON<|>Bellet M is one of the authors of the PRECISION study on aprocitentan for resistant hypertension\")\n##\n(\"entity\"<|>WEBER MA<|>PERSON<|>Weber MA is one of the authors of the PRECISION study on aprocitentan for resistant hypertension\")\n##\n(\"entity\"<|>TSAPAS A<|>PERSON<|>Tsapas A is one of the authors of the systematic review on glucose-lowering medications\")\n##\n(\"entity\"<|>KARAGIANNIS T<|>PERSON<|>Karagiannis T is one of the authors of the systematic review on glucose-lowering medications\")\n##\n(\"entity\"<|>KAKOTRICHI P<|>PERSON<|>Kakotrichi P is one of the authors of the systematic review on glucose-lowering medications\")\n##\n(\"entity\"<|>SCHMIEDER RE<|>PERSON<|>Schmieder RE is one of the authors of the START-study on single-pill combinations in hypertensive patients\")\n##\n(\"entity\"<|>WASSMANN S<|>PERSON<|>Wassmann S is one of the authors of the START-study on single-pill combinations in hypertensive patients\")\n##\n(\"entity\"<|>PREDEL HG<|>PERSON<|>Predel HG is one of the authors of the START-study on single-pill combinations in hypertensive patients\")\n##\n(\"entity\"<|>ALBASRI A<|>PERSON<|>Albasri A is one of the authors of the systematic review on antihypertensive treatment and adverse events\")\n##\n(\"entity\"<|>HATTLE M<|>PERSON<|>Hattle M is one of the authors of the systematic review on antihypertensive treatment and adverse events\")\n##\n(\"entity\"<|>KOSHIARIS C<|>PERSON<|>Koshiaris C is one of the authors of the systematic review on antihypertensive treatment and adverse events\")\n##\n(\"entity\"<|>SICA DA<|>PERSON<|>Sica DA is one of the authors of the study on thiazide and loop diuretics\")\n##\n(\"entity\"<|>CARTER B<|>PERSON<|>Carter B is one of the authors of the study on thiazide and loop diuretics\")\n##\n(\"entity\"<|>CUSHMAN W<|>PERSON<|>Cushman W is one of the authors of the study on thiazide and loop diuretics\")\n##\n(\"entity\"<|>李立明<|>PERSON<|>李立明 is one of the authors of the study on community-based prevention and treatment of primary hypertension\")\n##\n(\"entity\"<|>胡永华<|>PERSON<|>胡永华 is one of the authors of the study on community-based prevention and treatment of primary hypertension\")\n##\n(\"entity\"<|>曹卫华<|>PERSON<|>曹卫华 is one of the authors of the study on community-based prevention and treatment of primary hypertension\")\n##\n(\"entity\"<|>卫生部心血管病防治研究中心<|>ORGANIZATION<|>卫生部心血管病防治研究中心 is the organization that published the community disease management tutorial\")\n##\n(\"entity\"<|>梁小华<|>PERSON<|>梁小华 is one of the authors of the study on health management and direct medical costs of community hypertension patients\")\n##\n(\"entity\"<|>顾东风<|>PERSON<|>顾东风 is one of the authors of the study on health management and direct medical costs of community hypertension patients\")\n##\n(\"entity\"<|>张欢<|>PERSON<|>张欢 is one of the authors of the study on health management and direct medical costs of community hypertension patients\")\n##\n(\"entity\"<|>刘克军<|>PERSON<|>刘克军 is one of the authors of the health economics evaluation of ambulatory blood pressure monitoring in community hypertension diagnosis\")\n##\n(\"entity\"<|>陈伟伟<|>PERSON<|>陈伟伟 is one of the authors of the health economics evaluation of ambulatory blood pressure monitoring in community hypertension diagnosis\")\n##\n(\"entity\"<|>KRUM H<|>PERSON<|>Krum H is one of the authors of the study on catheter-based renal sympathetic denervation for resistant hypertension\")\n##\n(\"entity\"<|>SCHLAICH M<|>PERSON<|>Schlaich M is one of the authors of the study on catheter-based renal sympathetic denervation for resistant hypertension\")\n##\n(\"entity\"<|>WHITBOURN R<|>PERSON<|>Whitbourn R is one of the authors of the study on catheter-based renal sympathetic denervation for resistant hypertension\")\n##\n(\"entity\"<|>SYMPLICITY HTN-2 INVESTIGATORS<|>ORGANIZATION<|>Symplicity HTN-2 Investigators is the group that conducted the study on renal sympathetic denervation for resistant hypertension\")\n##\n(\"entity\"<|>ESLER MD<|>PERSON<|>Esler MD is one of the authors of the study on renal sympathetic denervation for resistant hypertension\")\n##\n(\"relationship\"<|>WILLIAMS B<|>MACDONALD TM<|>Williams B and MacDonald TM are co-authors of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>WILLIAMS B<|>MORANT S<|>Williams B and Morant S are co-authors of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>MACDONALD TM<|>MORANT S<|>MacDonald TM and Morant S are co-authors of the PATHWAY-2 study<|>8)\n##\n(\"relationship\"<|>YANO Y<|>HOSHIDE S<|>Yano Y and Hoshide S are co-authors of the JET study<|>8)\n##\n(\"relationship\"<|>YANO Y<|>TAMAKI N<|>Yano Y and Tamaki N are co-authors of the JET study<|>8)\n##\n(\"relationship\"<|>HOSHIDE S<|>TAMAKI N<|>Hoshide S and Tamaki N are co-authors of the JET study<|>8)\n##\n(\"relationship\"<|>B?RFACKER L<|>KUHL A<|>B?rfacker L and Kuhl A are co-authors of the study on BAY 94-8862<|>8)\n##\n(\"relationship\"<|>B?RFACKER L<|>HILLISCH A<|>B?rfacker L and Hillisch A are co-authors of the study on BAY 94-8862<|>8)\n##\n(\"relationship\"<|>KUHL A<|>HILLISCH A<|>Kuhl A and Hillisch A are co-authors of the study on BAY 94-8862<|>8)\n##\n(\"relationship\"<|>PATOULIAS D<|>PAPADOPOULOS C<|>Patoulias D and Papadopoulos C are co-authors of the study on finerenone<|>8)\n##\n(\"relationship\"<|>PATOULIAS D<|>KARAGIANNIS A<|>Patoulias D and Karagiannis A are co-authors of the study on finerenone<|>8)\n##\n(\"relationship\"<|>PAPADOPOULOS C<|>KARAGIANNIS A<|>Papadopoulos C and Karagiannis A are co-authors of the study on finerenone<|>8)\n##\n(\"relationship\"<|>SIDHARTA PN<|>MELCHIOR M<|>Sidharta PN and Melchior M are co-authors of the study on aprocitentan<|>8)\n##\n(\"relationship\"<|>SIDHARTA PN<|>KANKAM MK<|>Sidharta PN and Kankam MK are co-authors of the study on aprocitentan<|>8)\n##\n(\"relationship\"<|>MELCHIOR M<|>KANKAM MK<|>Melchior M and Kankam MK are co-authors of the study on aprocitentan<|>8)\n##\n(\"relationship\"<|>SCHLAICH MP<|>BELLET M<|>Schlaich MP and Bellet M are co-authors of the PRECISION study<|>8)\n##\n(\"relationship\"<|>SCHLAICH MP<|>WEBER MA<|>Schlaich MP and Weber MA are co-authors of the PRECISION study<|>8)\n##\n(\"relationship\"<|>BELLET M<|>WEBER MA<|>Bellet M and Weber MA are co-authors of the PRECISION study<|>8)\n##\n(\"relationship\"<|>TSAPAS A<|>KARAGIANNIS T<|>Tsapas A and Karagiannis T are co-authors of the systematic review on glucose-lowering medications<|>8)\n##\n(\"relationship\"<|>TSAPAS A<|>KAKOTRICHI P<|>Tsapas A and Kakotrichi P are co-authors of the systematic review on glucose-lowering medications<|>8)\n##\n(\"relationship\"<|>KARAGIANNIS T<|>KAKOTRICHI P<|>Karagiannis T and Kakotrichi P are co-authors of the systematic review on glucose-lowering medications<|>8)\n##\n(\"relationship\"<|>SCHMIEDER RE<|>WASSMANN S<|>Schmieder RE and Wassmann S are co-authors of the START-study<|>8)\n##\n(\"relationship\"<|>SCHMIEDER RE<|>PREDEL HG<|>Schmieder RE and Predel HG are co-authors of the START-study<|>8)\n##\n(\"relationship\"<|>WASSMANN S<|>PREDEL HG<|>Wassmann S and Predel HG are co-authors of the START-study<|>8)\n##\n(\"relationship\"<|>ALBASRI A<|>HATTLE M<|>Albasri A and Hattle M are co-authors of the systematic review on antihypertensive treatment<|>8)\n##\n(\"relationship\"<|>ALBASRI A<|>KOSHIARIS C<|>Albasri A and Koshiaris C are co-authors of the systematic review on antihypertensive treatment<|>8)\n##\n(\"relationship\"<|>HATTLE M<|>KOSHIARIS C<|>Hattle M and Koshiaris C are co-authors of the systematic review on antihypertensive treatment<|>8)\n##\n(\"relationship\"<|>SICA DA<|>CARTER B<|>Sica DA and Carter B are co-authors of the study on thiazide and loop diuretics<|>8)\n##\n(\"relationship\"<|>SICA DA<|>CUSHMAN W<|>Sica DA and Cushman W are co-authors of the study on thiazide and loop diuretics<|>8)\n##\n(\"relationship\"<|>CARTER B<|>CUSHMAN W<|>Carter B and Cushman W are co-authors of the study on thiazide and loop diuretics<|>8)\n##\n(\"relationship\"<|>李立明<|>胡永华<|>李立明 and 胡永华 are co-authors of the study on community-based prevention and treatment of primary hypertension<|>8)\n##\n(\"relationship\"<|>李立明<|>曹卫华<|>李立明 and 曹卫华 are co-authors of the study on community-based prevention and treatment of primary hypertension<|>8)\n##\n(\"relationship\"<|>胡永华<|>曹卫华<|>胡永华 and 曹卫华 are co-authors of the study on community-based prevention and treatment of primary hypertension<|>8)\n##\n(\"relationship\"<|>梁小华<|>顾东风<|>梁小华 and 顾东风 are co-authors of the study on health management and direct medical costs of community hypertension patients<|>8)\n##\n(\"relationship\"<|>梁小华<|>张欢<|>梁小华 and 张欢 are co-authors of the study on health management and direct medical costs of community hypertension patients<|>8)\n##\n(\"relationship\"<|>顾东风<|>张欢<|>顾东风 and 张欢 are co-authors of the study on health management and direct medical costs of community hypertension patients<|>8)\n##\n(\"relationship\"<|>刘克军<|>陈伟伟<|>刘克军 and 陈伟伟 are co-authors of the health economics evaluation of ambulatory blood pressure monitoring in community hypertension diagnosis<|>8)\n##\n(\"relationship\"<|>KRUM H<|>SCHLAICH M<|>Krum H and Schlaich M are co-authors of the study on renal sympathetic denervation<|>8)\n##\n(\"relationship\"<|>KRUM H<|>WHITBOURN R<|>Krum H and Whitbourn R are co-authors of the study on renal sympathetic denervation<|>8)\n##\n(\"relationship\"<|>SCHLAICH M<|>WHITBOURN R<|>Schlaich M and Whitbourn R are co-authors of the study on renal sympathetic denervation<|>8)\n##\n(\"relationship\"<|>ESLER MD<|>SYMPLICITY HTN-2 INVESTIGATORS<|>Esler MD is part of the Symplicity HTN-2 Investigators group<|>8)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_70f73d5ee2f16179e63fd202fe3a48e708371eb3b31e0c07a00726f16006d7f3_v2"}